S-1/A: Moleculin Biotech Launches Public Offering Amidst Nasdaq Compliance Concerns and Short Cash Runway

Moleculin Biotech, Inc. is conducting a 'reasonable best efforts' public offering of common stock and Series E warrants to fund its clinical development, particularly its lead drug Annamycin for AML, while simultaneously facing a Nasdaq non-compliance notice regarding its stockholders' equity.

Summary

• Moleculin Biotech, Inc. is a late-stage pharmaceutical development company focused on oncology, with its lead drug Annamycin (naxtarubicin) in a pivotal Phase 3 MIRACLE trial for relapsed/refractory (R/R) acute myeloid leukemia (AML).
• Interim unblinding of data for the Phase 3 MIRACLE trial is anticipated by the end of 2025, with an additional unblinding in the first half of 2026.
• The company is offering up to 10,869,565 shares of common stock and up to 32,608,696 accompanying Series E warrants, with an assumed combined public offering price of $0.69 per share and warrant, based on the June 5, 2025 Nasdaq closing price.
• Pre-funded warrants are also available for investors whose purchase of common stock would result in beneficial ownership exceeding 4.99% (or 9.99%), with an exercise price of $0.001 per share.
• The estimated net proceeds from this offering are approximately $6.8 million if fully subscribed, or $5.0 million if 75% of the securities are sold, after deducting placement agent fees and estimated offering expenses.
• On May 23, 2025, Moleculin Biotech received a Nasdaq non-compliance letter for failing to meet the minimum $2.5 million stockholders' equity requirement and other listing alternatives; the company has 45 days to submit a compliance plan.
• The exercisability of the Series E warrants is contingent upon stockholder approval, and their exercise price is subject to downward adjustment based on future dilutive issuances or share combination events, with a floor price not less than 20% of the lower of the closing price immediately preceding the offering or the average closing price for the five trading days immediately preceding the offering (assumed $0.14).
• If the Series E warrants' exercise price is reduced to the assumed floor price of $0.14, the total number of shares potentially issuable under these warrants could reach 160,714,286.
• As of March 31, 2025, the company's net tangible book value was negative ($11.1) million, or ($0.79) per share; after the offering, it is projected to be $(0.20) per share.
• The company's existing cash and cash equivalents as of March 31, 2025, are projected to fund operations into Q3 2025; with the offering proceeds, this runway is extended only into Q4 2025 (at maximum proceeds) or Q3 2025 (at 75% proceeds).

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to critical financial challenges, including Nasdaq non-compliance and a very short cash runway, which necessitate a 'best efforts' capital raise with no guaranteed minimum. While clinical progress with Annamycin is highlighted, the significant potential for shareholder dilution and the urgent need for further financing overshadow these positive developments, creating high uncertainty and risk for investors.

Positives

• Annamycin is advancing into a pivotal Phase 3 MIRACLE trial for R/R AML, with early interim data unblinding expected by the end of 2025 and additional unblinding in H1 2026, providing unique early visibility for a registration-enabling trial.
• Annamycin has demonstrated no evidence of cardiotoxicity in 84 subjects across five clinical trials, including 56 subjects treated above the FDA's lifetime maximum anthracycline limit of 550 mg/m2, with one subject reaching 3,420 mg/m2 (approximately five times the FDA limit).
• The company possesses two additional drug portfolios, WP1066 and WP1122, targeting hard-to-treat cancers and viruses, with some candidates already in Phase 1B/2 or Phase 2 clinical trials.
• Moleculin Biotech has a robust clinical pipeline with multiple active INDs/CTAs and has completed or is progressing through fourteen clinical trials.
• The WP1066 program is actively recruiting for a Phase 1B/2 trial in combination with radiation for Glioblastoma Multiforme (GBM) at Northwestern University.

Negatives

• The company is not in compliance with Nasdaq's Listing Rule 5550(b)(1) regarding minimum stockholders' equity ($2.5 million) and other listing alternatives, posing a risk of delisting.
• The offering is on a 'reasonable best efforts' basis with no minimum amount of securities required to be sold, which means the company may not raise sufficient capital to achieve its business plans.
• Purchasers in this offering will experience immediate and substantial dilution in net tangible book value, with the as-adjusted net tangible book value per share projected to be negative $(0.20) after the offering.
• The exercisability of the Series E warrants is contingent upon obtaining stockholder approval, and there is no guarantee that such approval will be secured, potentially rendering the warrants valueless.
• The potential issuance of up to 160,714,286 shares under the Series E warrants if the exercise price drops to the floor price significantly exceeds current authorized shares, requiring further stockholder approval for an increase in authorized shares.
• The company will require substantial additional financing in the near term beyond the proceeds from this offering to complete clinical development and commercialize Annamycin, and there is no assurance such capital will be available on acceptable terms.
• The Series E warrants include price protection and reset features that could lead to significant dilution for existing stockholders if the common stock price declines.
• There is no established public trading market for the common warrants or pre-funded warrants, which will limit their liquidity.
• The company's cash runway is very short, with existing cash funding operations only into Q3 2025, and the offering proceeds extending it only into Q3 or Q4 2025, indicating persistent financial pressure.

Risks

• The exercisability of the common warrants is contingent upon obtaining Warrant Stockholder Approval and potentially approval to increase authorized shares of common stock; failure to obtain these approvals means common warrants may never become exercisable or fully exercisable.
• The company has broad discretion in how it uses the proceeds of this offering, and these proceeds may not yield a significant return or any return at all for stockholders.
• The market price of the company's common stock could be subject to wide fluctuations due to various factors beyond its control, including general economic, political, and market conditions.
• The company will require substantial additional capital funding, which may not be available on acceptable terms or at all, potentially leading to delays, limitations, reductions, or cessation of operations and further dilution of common stock.
• The company does not intend to pay dividends in the foreseeable future.
• Purchasers in this offering may experience immediate and substantial dilution in net tangible book value.
• Future issuances of common or preferred stock to raise capital, finance acquisitions, or for strategic transactions would reduce the percentage ownership of existing stockholders and be dilutive to earnings per share.
• The common warrants are speculative in nature, and there is no assurance that their market value will equal or exceed their exercise price, or that exercising them will ever be profitable.
• Purchasers who enter into a securities purchase agreement may have rights not available to other purchasers, including breach of contract claims and specific covenants.
• The 'best efforts' nature of the offering means no minimum amount of securities is guaranteed to be sold, which may significantly reduce the amount of proceeds received by the company and hinder its ability to support continued operations.
• The company may be required to repurchase common warrants in the event of a Fundamental Transaction, which could materially adversely affect its financial condition and/or results of operations and may prevent or deter a third party from acquiring the company.
• The company is not in compliance with Nasdaq's continued listing requirements, and delisting could occur, adversely affecting its ability to raise additional financing, the ability of investors to trade securities, and the value and liquidity of common stock.
• The Series E warrants will be accounted for as a warrant liability at fair value, and subsequent changes in fair value will be reported in earnings, potentially having an adverse effect on net income and stockholders' equity, and hindering Nasdaq compliance.
• The company's officers, directors, and certain stockholders are subject to a 60-day lock-up period, and the company itself has agreed to similar restrictions on equity sales for 60 days and variable rate transactions for 180 days following stockholder approvals.

Future Outlook

The company anticipates interim unblinding of data for its pivotal Phase 3 MIRACLE trial for Annamycin by the end of 2025, with an additional unblinding in the first half of 2026. It intends to use the net proceeds from this offering to advance Annamycin and its other two drug portfolios through clinical development, preclinical studies, and into INDs or their equivalent, as well as for general working capital. The company plans to engage with the FDA and EMA regarding the possibility of conducting a single-arm accelerated pivotal trial for Annamycin in R/R AML. Despite the current offering, the company acknowledges it will require substantial additional financing in the near term to complete clinical development and commercialize Annamycin.

Management Comments

• "One of our core management beliefs is that anthracyclines represent one of the most important treatments for AML and Advanced STS, and we believe Annamycin may, for the first time ever, allow a majority of these patients to benefit from this treatment."
• "We believe that such a benefit could be disruptive to the competitive landscape for these markets."
• "This belief, coupled with our limited resources, leads us to currently focus mainly on the development of Annamycin."
• "We intend to advance our other drug candidates via investigator led studies – both clinically and preclinically."
• "Although we have not definitively concluded that Annamycin is incapable of cardiotoxicity, we discuss Annamycin’s lack of demonstrated cardiotoxicity in this document, corporate presentations and other public communications."

Industry Context

Moleculin Biotech's Annamycin is positioned as a next-generation anthracycline, a class of chemotherapy drugs widely used but limited by cardiotoxicity and multidrug resistance. Annamycin is specifically designed to overcome these limitations. The company highlights a recent retrospective study (C Larson, et al. JAMA Network Open. 2023) indicating that the incidence of heart failure more than doubles for cancer patients treated with anthracyclines compared to those not receiving them, underscoring the critical need for less cardiotoxic alternatives. Moleculin believes Annamycin's potential to allow more AML and Advanced STS patients to benefit from anthracycline treatment without cardiotoxicity could be 'disruptive to the competitive landscape' in these markets.

Comparison to Industry Standards

• Annamycin is designed to avoid multidrug resistance and be non-cardiotoxic, differentiating it from currently approved anthracyclines which are limited by these issues.
• Clinical data from 84 subjects across five trials show no evidence of cardiotoxicity for Annamycin, with 56 subjects treated above the FDA's lifetime maximum anthracycline limit of 550 mg/m2, including one subject reaching 3,420 mg/m2 (approximately five times the FDA approved lifetime anthracycline exposure). This contrasts significantly with the known cardiotoxic effects of conventional anthracyclines.
• A retrospective study published in JAMA Network Open (C Larson, et al. 2023) reported that heart failure incidence more than doubles for cancer patients treated with anthracyclines compared to those not receiving them, highlighting Annamycin's potential advantage in addressing a major limitation of standard anthracycline therapies.

Corporate Governance

Related Party Transactions

• In Q3 2022, the company entered into a portfolio advisory agreement with a related party entity, granting warrants to purchase 16,667 shares of common stock.
• In December 2023, several executive officers, advisors, and a member of the board of directors participated as investors in the company's registered direct offering and concurrent private placement.
• The company states that, except as disclosed in Schedule 3.1(r) (not provided), no officers, directors, or employees are party to transactions with the company or its subsidiaries exceeding $120,000, other than for salary, consulting fees, expense reimbursement, and other employee benefits including stock options.

Stakeholder Impact

• **Shareholders**: Face significant potential for dilution from the current offering and future capital raises, immediate reduction in net tangible book value, and the risk of delisting from Nasdaq, which could severely impact liquidity and share value. No dividends are expected in the foreseeable future.
• **New Investors in this Offering**: Will experience immediate and substantial dilution in net tangible book value. The value of the common warrants is contingent on stockholder approval, and their liquidity will be limited due to no established public trading market.
• **Employees**: May experience a loss of confidence if the company is delisted from Nasdaq, potentially affecting morale and retention.
• **Company Operations**: The 'best efforts' nature of the offering and the short cash runway indicate ongoing financial pressure, which could impact the speed and scope of clinical development programs if sufficient additional funding is not secured.

Next Steps

• Hold a special meeting of stockholders on or prior to 60 days after the consummation of this offering to obtain Warrant Stockholder Approval and Authorized Share Approval.
• If initial stockholder approval for warrants and authorized shares is not obtained, the company is obligated to call a meeting every 90 days thereafter until such approvals are secured or the common warrants are no longer outstanding.
• Advance Annamycin and the other two drug portfolios (WP1066 and WP1122) through clinical development and preclinical studies.
• Engage in discussions with the FDA and EMA regarding the potential for a single-arm accelerated pivotal trial for Annamycin in R/R AML.
• Submit a plan to Nasdaq within 45 calendar days from May 23, 2025, to address and regain compliance with the listing requirements.

Key Dates

Recommendation

Keywords

Biotechnology, Pharmaceutical Development, Oncology, Acute Myeloid Leukemia (AML), Annamycin, Series E Warrants, Public Offering, SEC Filing, Nasdaq Compliance, Clinical Trials, Drug Development, Cardiotoxicity, WP1066, WP1122, Pre-funded Warrants, Dilution, Capital Raise, MD Anderson Cancer Center, Anthracyclines, Soft Tissue Sarcoma (STS), MIRACLE trial